Two patents currently held, every record listed here
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
8 more records may belong here and await a decision; they are not counted.
The next term ends in Dec 2028. from the record
Of the 4 now held by other companies, 4 name Inflammx Therapeutics Inc. as their current owner. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
2
Ending by 2030
Dec 2028
Next term end
2
Patent families
When these terms end
Each bar runs from grant to computed term end. 2017 to 2039.20222027203220372039
A dotted end marks a recorded terminal disclaimer this site has not resolved: the term can only be shorter than the bar, never longer.
5 pending applications: term is not computable until grant.Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends no later than Dec 2028 · Medium confidence
Also notable
Ends Dec 2028 · High confidence
Medical Devices
US 9,561,311
The largest patent family in this portfolio, 5 related applications, renewed at every maintenance window due so far. Protection runs to 2028. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Treatment of Fibrotic Conditions
US 9,738,892
Granted 2017 and renewed at every maintenance window due so far. Protection runs to 2028. A terminal disclaimer caps this term to an earlier patent's.
Formerly held, still cited
Notable
Ends Aug 2035 · High confidence
The most cited patent in this portfolio, cited by 15 later US patents, top 25% of utility patents granted in 2019 in our data. Protection runs to 2035.
now held by Inflammx Therapeutics, Inc.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 17, 2027.
Recent changes
- 1 of the patents on this record was granted since Aug 20, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Treatment of Fibrotic Conditions | 1 in force | to Dec 2028 |
| Medical Devices | 1 in force | to Dec 2028 |
Patents held now
Soonest term end first.
Showing 1 to 2 of 2
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,561,311 | Medical Devices In force · Medium confidence | In force | Medium confidence | |
| US 9,738,892 | Treatment of Fibrotic Conditions In force · High confidence | In force | High confidence |
Also on record, not counted in the 2: 4 patents in force now held by others · 28 patents ended · 5 applications pending · 9 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
3 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed